Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 13/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788309 | 0.89 | USP2 (0.58) | USP2POLBALDH1A1L3MBTL1IDH1 | |
| SCHEMBL12639693 | 0.89 | USP2 (0.73) | USP2POLBALDH1A1L3MBTL1KDM4E | |
| SCHEMBL14788380 | 0.88 | USP2 (0.60) | USP2POLBALDH1A1L3MBTL1IDH1 | |
| SCHEMBL14788515 | 0.88 | USP2 (0.63) | USP2POLBALDH1A1L3MBTL1IDH1 | |
| SCHEMBL14788601 | 0.87 | USP2 (0.62) | USP2POLBALDH1A1L3MBTL1IDH1 | |
| SCHEMBL12696356 | 0.84 | USP2 (0.62) | USP2POLBALDH1A1L3MBTL1KDM4E | |
| SCHEMBL14788384 | 0.77 | USP2 (0.51) | USP2POLBALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12639698 | 0.76 | MAPT (0.58) | USP2ALDH1A1L3MBTL1IDH1TSHR | |
| SCHEMBL12696371 | 0.75 | MAPT (0.42) | IDH1TSHRMAPT | |
| SCHEMBL12639513 | 0.74 | IDH1 (0.47) | IDH1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2013-03-21 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2009150248-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | CYTOMICS SYSTEMS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071328-A1 | Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon | RELA, NFE2, NCOA1 | USP2 1440/4885POLB 3598/4885ALDH1A1 1558/4885 |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | VHL, CYP11B2, SLC10A1 | USP2 4767/4885POLB 1374/4885ALDH1A1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.